

Toralf Reimer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8624069/publications.pdf>

Version: 2024-02-01

43
papers

1,179
citations

516710

16
h-index

414414

32
g-index

45
all docs

45
docs citations

45
times ranked

1386
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy. <i>Annals of Surgery</i> , 2022, 275, 576-581.	4.2	38
2	Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery. <i>Journal of Clinical Oncology</i> , 2022, 40, 1903-1915.	1.6	31
3	Abstract P5-13-36: Germline <i>BRCA1/2</i> and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022, 82, P5-13-36-P5-13-36.	0.9	0
4	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. <i>Cancer Research</i> , 2022, 82, PD2-04-PD2-04.	0.9	0
5	Abstract GS4-03: Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA,) Tj ETQq1 1 0.784314 rgBT / Ov cancer. <i>Cancer Research</i> , 2022, 82, GS4-03-GS4-03.	0.9	4
6	The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. <i>British Journal of Cancer</i> , 2022, 126, 1715-1724.	6.4	14
7	Abstract OT1-02-01: Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA. <i>Cancer Research</i> , 2022, 82, OT1-02-01-OT1-02-01.	0.9	0
8	False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 589-595.	2.5	14
9	Radiological Underestimation of Tumor Size as a Relevant Risk Factor for Positive Margin Rate in Breast-Conserving Therapy of Pure Ductal Carcinoma In Situ (DCIS). <i>Cancers</i> , 2022, 14, 2367.	3.7	2
10	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. <i>Journal of Clinical Oncology</i> , 2021, 39, 518-518.	1.6	2
11	The Clinical Relevance of Target Lymph Node Biopsy after Primary Systemic Therapy in Initially Node-Positive Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 2620.	3.7	2
12	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	1.6	153
13	Lost clips after targeted lymph node biopsy in breast cancer patients: Follow-up of the CLIP-study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1907-1912.	1.0	5
14	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 1151-1161.	10.7	248
15	Prevalence, Clinical Significance and Risk Factors for Developing Scar Pain and Sensibility Disorders in Breast Cancer Patients after Breast-Conserving Therapy and Mastectomy. <i>Breast Care</i> , 2021, 16, 1-9.	1.4	1
16	Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. <i>Cancers</i> , 2020, 12, 3698.	3.7	33
17	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. <i>Breast Care</i> , 2020, 15, 294-309.	1.4	47
18	Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 683-693.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Oncologic Outcome of Patients with (Low-Risk) Endometrial Carcinoma Undergoing Laparotomy versus Minimally Invasive Hysterectomy: A Retrospective Analysis. <i>Oncology Research and Treatment</i> , 2019, 42, 636-649.	1.2	2
20	A gap analysis of opportunities and priorities for breast surgical research. <i>Lancet Oncology</i> , The, 2019, 20, e1.	10.7	1
21	Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 249-256.	2.5	15
22	Distinct Ezrin Truncations Differentiate Metastases in Sentinel Lymph Nodes from Unaffected Lymph Node Tissues, from Primary Breast Tumors, and from Healthy Glandular Breast Tissues. <i>Translational Oncology</i> , 2018, 11, 1-10.	3.7	7
23	Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery. <i>Breast Care</i> , 2018, 13, 324-330.	1.4	22
24	What Is the Best Management of cN0pN1 (sn) Breast Cancer Patients. <i>Breast Care</i> , 2018, 13, 331-336.	1.4	13
25	Radiation Sensitivity of Adipose-Derived Stem Cells Isolated from Breast Tissue. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1988.	4.1	6
26	Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1307-1311.	1.0	81
27	RESPONDER " diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. <i>BMC Cancer</i> , 2018, 18, 851.	2.6	32
28	Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xECâ†'4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 504-504.	1.6	10
29	Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5611-TPS5611.	1.6	0
30	SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. <i>BMC Cancer</i> , 2016, 16, 337.	2.6	17
31	Acute-phase proteins in prediction of preeclampsia in patients with abnormal midtrimester uterine Doppler velocimetry. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1151-1160.	1.7	11
32	Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 556-556.	1.6	4
33	Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 557-557.	1.6	91
34	Diagnosis of Ruptured Breast Implants Through High-Resolution Ultrasound Combined With Real-Time Elastography. <i>Aesthetic Surgery Journal</i> , 2015, 35, 410-418.	1.6	10
35	Primary Metastatic Breast Cancer: The Impact of Locoregional Therapy. <i>Breast Care</i> , 2014, 9, 23-28.	1.4	16
36	Influence of Lifestyle Factors on Breast Cancer Risk. <i>Breast Care</i> , 2014, 9, 407-414.	1.4	51

#	ARTICLE	IF	CITATIONS
37	Local Treatment of the Axilla in Early Breast Cancer: Concepts from the National Surgical Adjuvant Breast and Bowel Project B-04 to the Planned Intergroup Sentinel Mamma Trial. <i>Breast Care</i> , 2014, 9, 87-87.	1.4	68
38	Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 263-269.	1.5	31
39	A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 5080-5080.	1.6	5
40	Quality-of-Life Considerations in the Treatment of Early-Stage Breast Cancer in the Elderly. <i>Drugs and Aging</i> , 2010, 27, 791-800.	2.7	43
41	How Important is the Axillary Nodal Status for Adjuvant Treatment Decisions at a Breast Cancer Multidisciplinary Tumor Board? A Survival Analysis. <i>Annals of Surgical Oncology</i> , 2008, 15, 472-477.	1.5	10
42	Value of Axillary Surgery for Postoperative Therapy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 2980-2980.	1.5	0
43	Immunohistochemically Detected Lymph-Node Micrometastases in Breast Cancer and their Correlation with Prognostic Factors. <i>Breast Journal</i> , 1997, 3, 106-111.	1.0	15